Prognosis
Pfizer Covid Vaccine Trial Hasn’t Reached Analysis Milestone
- Virus cases among trial participants short of key threshold
- As trial progresses, drugmaker narrows guidance for year
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Pfizer Inc.’s late-stage trial of an experimental coronavirus vaccine hasn’t yet reached a key milestone that will help researchers determine how well it protects people from Covid-19.